Met Life Investment Management, LLC Arcutis Biotherapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $14.7 Billion
- Q1 2024
A detailed history of Met Life Investment Management, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 43,801 shares of ARQT stock, worth $407,349. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,801Holding current value
$407,349% of portfolio
0.0%Shares
32 transactions
Others Institutions Holding ARQT
# of Institutions
172Shares Held
126MCall Options Held
498KPut Options Held
1.64M-
Jennison Associates LLC12.2MShares$113 Million0.08% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$81.7 Million4.57% of portfolio
-
State Street Corp Boston, MA8.78MShares$81.7 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.88MShares$73.3 Million3.34% of portfolio
-
Rubric Capital Management LP New York, NY7.51MShares$69.8 Million2.54% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $560M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...